Drug Profile
Apimostinel - AbbVie
Alternative Names: AGN 241660; GATE-202; NRX-1074Latest Information Update: 09 Nov 2023
Price :
$50
*
At a glance
- Originator Naurex
- Developer AbbVie; Gate Neurosciences; Naurex
- Class Amides; Antidepressants; Small molecules
- Mechanism of Action NMDA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 07 Nov 2023 Biomarker and adverse events data from a phase I trial in healthy volunteers released by Gate Neurosciences
- 04 Apr 2023 Gate Neurosciences completes the GATE-202 trial for Major depressive disorder (In volunteers) in USA (IV) (NCT05597241)
- 08 Dec 2022 Apimostinel is still in phase I trials for Major depressive disorder in USA